The drugs in question, which are sold in Lebanon, Jordan, Syria, Libya and Yemen, are off patent medicines that generated revenues of $11.8m in 2008.
In recent months GlaxoSmithKline (GSK), in common with many of its Big Pharma rivals, has been building its presence in emerging pharmaceutical markets in a bid to broaden its revenue stream.
Late last year, GSK bought several other generic drugs from BMS’ Pakistani and Egyptian product portfolios as well as a manufacturing plant in Cairo.
